Minimally Invasive Cancer Therapies APPG

First Registered: 02/06/2021 • Last updated on: 06/10/2021

Official Page

To drive awareness of minimally invasive cancer therapies and to ensure that eligible patients across the UK can have timely access.

Note: All-Party Parliamentary Groups (APPGs) are informal, cross-party groups formed by MPs and Members of the House of Lords who share a common interest in a particular policy area, region or country. APPGs have no official status within Parliament.


This content was generated for your convenience by Parallel Parliament and does not form part of the official record.
Recent Documents related to Minimally Invasive Cancer Therapies

1. Minimally invasive cancer therapies
03/02/2021 - Early Day Motions

Found: That this House welcomes World Cancer Day on 4 February 2021 and supports NHS efforts to deliver world

2. Minimally Invasive Cancer Therapies
02/06/2021 - APPGs

Found: To drive awareness of minimally invasive cancer therapies and to ensure that eligible patients across

3. General Debate on the spending of the Department of Health on Non-Invasive Precision Therapies for cancer
17/07/2019 - Parliamentary Research

Found: Health and Social Care on Non-Invasive Precision Therapies for Cancer By Tom Powell Michael O'Donnell

4. Innovate UK funding competition winners 2017
12/11/2019 - Innovate UK
- View source

Found: biopsy and sequencing technology for detecting cancer gene mutations in blood £500,000 £350,000 Note:

5. Non-tech summaries 2016: projects on cardiovascular disorders
21/12/2017 - Home Office
- View source

Found: infarction (myocardial infarction) preclinical therapies for pulmonary hypertension (cardiovascular, pulmonary

Latest Documents
Recent Speeches related to Minimally Invasive Cancer Therapies

1. Non-invasive Precision Cancer Therapies
18/07/2019 - Commons Chamber

1: recognises the vital role that radiotherapy plays in cancer treatment across the UK with an estimated one in - Speech Link
2: recognises the vital role that radiotherapy plays in cancer treatment across the UK with an estimated one in - Speech Link
3: therapy unit, which is going to be the future of cancer treatment. However, when I speak to the staff at - Speech Link

2. NHS: Cancer Treatments
25/01/2018 - Lords Chamber

1: what action they are taking to evaluate innovative cancer treatments and make them available through the - Speech Link
2: reshape the way we think about the treatment of cancer for people all over the world. In doing so, I thank - Speech Link

3. Covid-19: People with Neurological Conditions
27/05/2021 - Grand Committee

1: referrals and delays in access to medication, to therapies such as physio and speech therapy, for example - Speech Link
2: specialist trained staff to admit patients using non-invasive ventilation or even suctioning or were confused - Speech Link
3: resources for all long-term conditions, not just cancer, important though that is. Many neurological conditions - Speech Link

4. Gene Editing
30/01/2020 - Lords Chamber

1: future generations.Several CRISPR-related therapies are in early phase trials for somatic genomic - Speech Link
2: full genome sequencing of 100,000 patients with cancer or rare, infectious diseases, places the UK at - Speech Link
3: such as cystic fibrosis, muscular dystrophy and cancer.As our Library briefing makes clear, the - Speech Link

5. Cancer Strategy
22/02/2018 - Commons Chamber

1: move,That this House has considered the Cancer Strategy.Thank you, Madam Deputy Speaker - Speech Link

Latest Speeches
Recent Questions related to Minimally Invasive Cancer Therapies
1. Cancer
asked by: Tanmanjeet Singh Dhesi
06/11/2020
... and whether that includes data on the number of people diagnosed with secondary breast cancer.

2. Cancer
asked by: Helen Hayes
30/12/2020
... what data has been published from version 8 of the Cancer Outcomes and Services Dataset (COSD); and whether that includes data on the number of people diagnosed with secondary breast cancer.

3. Cancer
asked by: Diana Johnson
20/10/2020
... what steps his Department is taking to tackle the NHS backlog in cancer (a) screening and (b) treatment.

4. Cancer
asked by: Julian Sturdy
10/11/2020
... what comparative assessment his Department has made of the number of people diagnosed with cancer in (a) 2020 and (b) the last five years.

5. Cancer
asked by: Julian Sturdy
05/11/2020
... what assessment his Department has made of the effect of the covid-19 outbreak on cancer waiting times.

Latest Questions
APPG Supplied Content

APPGs can register with Parallel Parliament and submit files and articles to be placed here.

Parallel Parliament offers the facility for APPGs to submit written content and files, which are made available through this page.

Submitters can draft and edit publications, and either release them on demand, or schedule release for a future date.

Both text content and attached files submitted through this facility is indexed by our website, and made available through both the search function and relevant e-mail alerts. Any of our users registered for an alert which matches your content, will receive a link making them aware of its publication.

If you wish to register as an authorised representative of the Minimally Invasive Cancer Therapies APPG and use this facility, click below

7 Current APPG Officers
Holly Mumby-Croft Portrait
Holly Mumby-Croft
Officer
Conservative - Scunthorpe
Joined: 2nd June 2021
Contact Details

Registered Contact:

Greg Smith MP, House of Commons, London, SW1A 0AA. Tel: 0207 219 4287.

Email: greg.smith.mp@parliament.uk

Public Enquiry Point:

Mike Houghton, Healthcomms Consulting

Email: michael@healthcommsconsulting.co.uk

Secretariat:

Healthcomms Consulting acts as the group's secretariat. https://www.healthcommsconsulting.co.uk/

Benefits in Kind
Date
17 May 2021
Source
Healthcomms Consulting
Description
Secretariat   From : 17/05/2021 To : 16/05/2022   Cost Met : Healthcomms Consulting is paid by Boston Scientific and Sirtex Medical Ltd to act as the group's secretariat
Value
£19,501
Date
17 May 2021
Source
Healthcomms Consulting
Description
Healthcomms Consulting is paid by Boston Scientific and Sirtex Medical Ltd to act as the group's secretariat   From : 17/05/2021 To : 16/05/2022
Value
£19,501

No direct financial benefits are on record for the Minimally Invasive Cancer Therapies APPG